SA
Therapeutic Areas
CARGO Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CRG-022 | Large B-cell lymphoma (LBCL) post-CD19 CAR T relapse/refractory | Phase 2 |
Leadership Team at CARGO Therapeutics
GC
Gina Chapman
President, Chief Executive Officer, and Board Member
BH
Brett H. Hall, Ph.D.
Chief Scientific Officer
KM
Kristen M. Hege, M.D.
Senior Vice President, Early Clinical Development & Hematology/Oncology Therapy Area Lead
JP
James P. Bock, M.B.A.
Chief Financial Officer
HC
Hannah Chang, J.D.
General Counsel
SK
Steve Krognes
Chairman of the Board of Directors